Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :857
Small font sizeDefault font sizeIncrease font size
Read this article


    Article Cited by others


Aprepitant: A substance P antagonist for chemotherapy induced nausea and vomiting

Girish C, Manikandan S

Year : 2007| Volume: 44| Issue : 1 | Page no: 25-30

   This article has been cited by
1 Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial
Yi Cheng, Zehua Wu, Lishuo Shi, Cailu Shen, Jianwei Zhang, Huabin Hu, Weiwei Li, Yue Cai, Xiaoyu Xie, Jiayu Ling, Qin Zheng, Yanhong Deng
eClinicalMedicine. 2022; 49: 101480
[Pubmed]  [Google Scholar] [DOI]
2 The Neurokinin-1 Receptor: A Promising Antitumor Target
Rafael Coveñas, Francisco D. Rodríguez, Miguel Muñoz
Receptors. 2022; 1(1): 72
[Pubmed]  [Google Scholar] [DOI]
3 Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends
Kush Gupta, Rebecca Walton, S.P. Kataria
Cancer Treatment and Research Communications. 2021; 26: 100278
[Pubmed]  [Google Scholar] [DOI]
4 The 5-HT 3 Receptor Affects Rotavirus-Induced Motility
Marie Hagbom, Arash Hellysaz, Claudia Istrate, Johan Nordgren, Sumit Sharma, Felipe Meira de-Faria, Karl-Eric Magnusson, Lennart Svensson, Susana López
Journal of Virology. 2021; 95(15)
[Pubmed]  [Google Scholar] [DOI]
5 Investigation of the Role of Neurokinin-1 Receptor Inhibition Using Aprepitant in the Apoptotic Cell Death through PI3K/Akt/NF-?B Signal Transduction Pathways in Colon Cancer Cells
Atefeh Ghahremanloo, Hossein Javid, Amir R. Afshari, Seyed Isaac Hashemy, Riffat Mehboob
BioMed Research International. 2021; 2021: 1
[Pubmed]  [Google Scholar] [DOI]
6 Influence of glutathione S transferase A1 gene polymorphism (-69C?>?T, rs3957356) on intravenous cyclophosphamide efficacy and side effects: a case-control study in Egyptian patients with lupus nephritis
Doaa H. S. Attia, Mervat Eissa, Lamees A. Samy, Rasha A. Khattab
Clinical Rheumatology. 2021; 40(2): 753
[Pubmed]  [Google Scholar] [DOI]
7 Long-Term Daily Administration of Aprepitant for the Management of Intractable Nausea and Vomiting in Children With Life-Limiting Conditions: A Case Series
Bhumik Patel, Jonathan Downie, Julie Bayliss, Andrea Stephenson, Myra Bluebond-Langner
Journal of Pain and Symptom Management. 2021; 62(3): e225
[Pubmed]  [Google Scholar] [DOI]
8 Peptide-Liganded G Protein-Coupled Receptors as Neurotherapeutics
Lee E. Eiden, Ki Ann Goosens, Kenneth A. Jacobson, Lorenzo Leggio, Limei Zhang
ACS Pharmacology & Translational Science. 2020; 3(2): 190
[Pubmed]  [Google Scholar] [DOI]
9 Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting
James Gilmore,Alberto Bernareggi
The Journal of Clinical Pharmacology. 2019; 59(4): 472
[Pubmed]  [Google Scholar] [DOI]
10 Application of analytical quality by design principles for the determination of alkyl p -toluenesulfonates impurities in Aprepitant by HPLC. Validation using total-error concept
Constantinos K. Zacharis,Elli Vastardi
Journal of Pharmaceutical and Biomedical Analysis. 2018; 150: 152
[Pubmed]  [Google Scholar] [DOI]
11 Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-?B axis: Shedding new light on resistance to Aprepitant
Davood Bashash,Ava Safaroghli-Azar,Samaneh Bayati,Elham Razani,Atieh Pourbagheri-Sigaroodi,Arshia Gharehbaghian,Majid Momeny,Maryam Sanjadi,Mostafa Rezaie-Tavirani,Seyed H. Ghaffari
The International Journal of Biochemistry & Cell Biology. 2018; 103: 105
[Pubmed]  [Google Scholar] [DOI]
12 Doxorubicin-Induced Myocardial Fibrosis Involves the Neurokinin-1 Receptor and Direct Effects on Cardiac Fibroblasts
Scott P. Levick,David R. Soto-Pantoja,Jianli Bi,W. Gregory Hundley,Alexander Widiapradja,Edward J. Manteufel,Tancia W. Bradshaw,Giselle C. Meléndez
Heart, Lung and Circulation. 2018;
[Pubmed]  [Google Scholar] [DOI]
13 Treatment of nausea with innovative antiemetics
Yuki Fujii,Hanae Ida,Tatsushi Shimokuni,Fumihiko Haraguchi
Expert Review of Quality of Life in Cancer Care. 2017; 2(2): 109
[Pubmed]  [Google Scholar] [DOI]
14 Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting
Anncarin Svanberg, Gunnar Birgegård
Oncology. 2015; 89(1): 31
[Pubmed]  [Google Scholar] [DOI]
15 Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients
Michelle C Janelsins,Mohamedtaki A Tejani,Charles Kamen,Anita R Peoples,Karen M Mustian,Gary R Morrow
Expert Opinion on Pharmacotherapy. 2013; 14(6): 757
[Pubmed]  [Google Scholar] [DOI]
16 Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients
Janelsins, M.C. and Tejani, M.A. and Kamen, C. and Peoples, A.R. and Mustian, K.M. and Morrow, G.R.
Expert Opinion on Pharmacotherapy. 2013; 14(6): 757-766
[Pubmed]  [Google Scholar]
17 Use of high-dose cisplatin with aprepitant in an outpatient setting
Furukawa, N. and Kawaguchi, R. and Kobayashi, H.
European Journal of Cancer Care. 2012; 21(4): 436-441
[Pubmed]  [Google Scholar]
18 Ondansetron in combination with gingerol suppresses cisplatin-induced pica in rats
Yang, Y.-L. and Yue, W. and Tian, Z.-B. and Wang, M.-L. and Yang, Z.-H. and Zhang, Q. and Wei, L.-Z. and Zhao, Q.-X. and Shi, Z.-Y.
World Chinese Journal of Digestology. 2011; 19(10): 1034-1039
[Pubmed]  [Google Scholar]
19 Use of high-dose cisplatin with aprepitant in an outpatient setting : Management of high-dose cisplatin administration
European Journal of Cancer Care. 2011; : no
[HTML Full text]  [Google Scholar] [DOI]
20 Pharmacological management of chemotherapy-induced nausea and vomiting in children with cancer
Cefalo, M.G., Ruggiero, A., Maurizi, P., Attinà, G., Arlotta, A., Riccardi, R.
Journal of Chemotherapy. 2009; 21(6): 605-610
[Pubmed]  [Google Scholar]
21 Chemotherapy-Induced Nausea and Vomiting: Challenges and Opportunities for Improved Patient Outcomes
Hawkins, R. and Grunberg, S.
Clinical Journal of Oncology Nursing. 2009; 13(1): 54-64
[Pubmed]  [Google Scholar]
22 Pharmacological Management of Chemotherapy-Induced Nausea and Vomiting in Children with Cancer
M.G. Cefalo,A. Ruggiero,P. Maurizi,G. Attinà,A. Arlotta,R. Riccardi
Journal of Chemotherapy. 2009; 21(6): 605
[Pubmed]  [Google Scholar] [DOI]
23 Pharmacological Characterization of T-2328, 2-Fluoro-4æ-methoxy-3æ-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1æ-biphenyl]-4-carbonitrile Dihydrochloride, as a Brain-Penetrating Antagonist of Tachykinin NK1 Receptor
Yumi Watanabe,Hidetoshi Asai,Taketoshi Ishii,Satoko Kiuchi,Masahito Okamoto,Hiroyuki Taniguchi,Masaaki Nagasaki,Akira Saito
Journal of Pharmacological Sciences. 2008; 106(1): 121
[Pubmed]  [Google Scholar] [DOI]
24 Aprepitant - Where do we stand in the control of chemotherapy-induced nausea and vomiting?
Sarcev, T., Secen, N., Zaric, B., Milovancev, A.
Journal of B.U.ON.. 2008; 13(3): 333-339
[Pubmed]  [Google Scholar]
25 Pharmacological Characterization of T-2328, 2-Fluoro-4æ-methoxy-3æ-[[[(2S, 3S)-2-phenyl-3-piperidinyl] amino] methyl]-[1, 1æ-biphenyl]-4-carbonitrile Dihydrochloride, as a Brain-Penetrating Antagonist of Tachykinin NK 1 Receptor
Watanabe, Y. and Asai, H. and Ishii, T. and Kiuchi, S. and Okamoto, M. and Taniguchi, H. and Nagasaki, M. and Saito, A.
Journal of Pharmacological Sciences. 2008; 106(1): 121-127
[Pubmed]  [Google Scholar]
26 Substance P and its receptors--a potential target for novel medicines in malignant brain tumour therapies (mini-review)
Neuropeptides, M. and Warsaw, P., Łazarczyk, M., Matyja, E., Lipkowski, A.
Folia Neuropathologica. 2007; 45(3): 99-107
[Pubmed]  [Google Scholar]


  Site Map | What's new | Copyright and Disclaimer | Privacy Notice
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow